Forxiga, a once-daily oral agent, provides physicians with a new option to improve glycaemic control as monotherapy in metformin-intolerant patients or combination therapy Reduction of weight and ...
AstraZeneca AZN announced that the European Medicines Agency has accepted the Marketing Authorization Variation (MAV) for the label expansion of Forxiga (dapagliflozin). Forxiga, a selective SGLT-2 ...
In a shocking, yet low-key, announcement, the sodium-glucose transporter 2 (SGLT2) inhibitor dapagliflozin (Forxiga, AstraZeneca) has been withdrawn from the market in all EU countries for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback